(-0.08%) 5 304.25 points
(-0.09%) 40 140 points
(-0.05%) 18 465 points
(-0.07%) $83.11
(-0.62%) $1.752
(0.73%) $2 254.80
(0.74%) $25.10
(0.21%) $923.00
(0.07%) $0.927
(0.15%) $10.86
(0.03%) $0.792
(-0.21%) $92.38
Live Chart Being Loaded With Signals
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz...
Stats | |
---|---|
Today's Volume | 1.52M |
Average Volume | 1.44M |
Market Cap | 189.25B |
EPS | $0 ( 2024-01-31 ) |
Next earnings date | ( $1.720 ) 2024-04-23 |
Last Dividend | $3.47 ( 2023-03-09 ) |
Next Dividend | $0 ( N/A ) |
P/E | 23.59 |
ATR14 | $0.0280 (0.03%) |
Volume Correlation
Novartis AG Correlation
10 Most Positive Correlations |
---|
10 Most Negative Correlations |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Novartis AG Correlation - Currency/Commodity
Novartis AG Financials
Annual | 2023 |
Revenue: | $46.66B |
Gross Profit: | $34.19B (73.27 %) |
EPS: | $7.15 |
Q4 | 2023 |
Revenue: | $11.78B |
Gross Profit: | $8.75B (74.34 %) |
EPS: | $4.14 |
Q3 | 2023 |
Revenue: | $12.09B |
Gross Profit: | $8.98B (74.22 %) |
EPS: | $0.850 |
Q2 | 2023 |
Revenue: | $13.94B |
Gross Profit: | $9.60B (68.85 %) |
EPS: | $1.110 |
Financial Reports:
No articles found.
Novartis AG Dividends
(Q3/22) | (Q4/22) | (Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0 (N/A) |
$3.47 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.966 | 2000-11-14 |
Last Dividend | $3.47 | 2023-03-09 |
Next Dividend | $0 | N/A |
Payout Date | 2023-03-20 | |
Next Payout Date | N/A | |
# dividends | 23 | -- |
Total Paid Out | $44.60 | -- |
Avg. Dividend % Per Year | 2.46% | -- |
Score | 4.3 | -- |
Div. Sustainability Score | 10.00 | |
Div.Growth Potential Score | 5.17 | |
Div. Directional Score | 8.61 | -- |
Year | Amount | Yield |
---|---|---|
2000 | $0.966 | 2.96% |
2001 | $0.450 | 1.12% |
2002 | $0.468 | 1.46% |
2003 | $0.627 | 1.89% |
2004 | $0.722 | 1.57% |
2005 | $0 | 0.00% |
2006 | $0.801 | 1.50% |
2007 | $0.969 | 1.67% |
2008 | $1.319 | 2.42% |
2009 | $1.541 | 3.11% |
2010 | $1.780 | 3.38% |
2011 | $2.11 | 3.56% |
2012 | $2.20 | 3.78% |
2013 | $2.27 | 3.56% |
2014 | $2.44 | 3.10% |
2015 | $2.52 | 2.73% |
2016 | $2.47 | 2.88% |
2017 | $2.46 | 3.38% |
2018 | $2.67 | 3.15% |
2019 | $2.57 | 3.06% |
2020 | $3.04 | 3.20% |
2021 | $3.38 | 3.58% |
2022 | $3.36 | 3.82% |
2023 | $3.47 | 3.76% |
2024 | $0 | 0.00% |
The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. However, its Dividend Growth Potential Score (DGPS) is only moderate, indicating limited growth potential. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
LOMA | Dividend Knight | 2023-06-30 | Quarterly | 2 | 5.23% | 8.53 |
SBR | Dividend Royal | 2023-11-14 | Monthly | 38 | 7.74% | 8.50 |
MTR | Dividend Royal | 2023-10-30 | Monthly | 39 | 10.10% | 8.50 |
GOF | Dividend Royal | 2023-11-14 | Monthly | 18 | 8.03% | 8.50 |
SCM | Dividend King | 2023-12-15 | Monthly | 13 | 7.08% | 8.50 |
KIO | Dividend Royal | 2023-12-14 | Monthly | 12 | 7.05% | 8.50 |
SJT | Dividend Royal | 2023-11-29 | Monthly | 39 | 12.52% | 8.50 |
PHK | Dividend Royal | 2023-11-10 | Monthly | 22 | 6.88% | 8.50 |
NCV | Dividend Royal | 2024-02-09 | Monthly | 22 | 7.68% | 8.50 |
JQC | Dividend Royal | 2023-11-14 | Monthly | 22 | 6.56% | 8.50 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0.291 | 1.500 | 4.18 | 6.27 | [0 - 0.5] |
returnOnAssetsTTM | 0.149 | 1.200 | 5.05 | 6.06 | [0 - 0.3] |
returnOnEquityTTM | 0.315 | 1.500 | 7.61 | 10.00 | [0.1 - 1] |
payoutRatioTTM | 0.498 | -1.000 | 5.02 | -5.02 | [0 - 1] |
currentRatioTTM | 1.155 | 0.800 | 9.22 | 7.38 | [1 - 3] |
quickRatioTTM | 0.884 | 0.800 | 9.50 | 7.60 | [0.8 - 2.5] |
cashRatioTTM | 0.508 | 1.500 | 8.29 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.264 | -1.500 | 5.61 | -8.41 | [0 - 0.6] |
interestCoverageTTM | 11.58 | 1.000 | 6.82 | 6.82 | [3 - 30] |
operatingCashFlowPerShareTTM | 7.05 | 2.00 | 7.65 | 10.00 | [0 - 30] |
freeCashFlowPerShareTTM | 5.62 | 2.00 | 7.19 | 10.00 | [0 - 20] |
debtEquityRatioTTM | 0.565 | -1.500 | 7.74 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0.717 | 1.000 | 1.375 | 1.375 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0.198 | 1.000 | 8.03 | 8.03 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | 0.549 | 1.000 | 8.06 | 8.06 | [0.2 - 2] |
assetTurnoverTTM | 0.510 | 0.800 | 9.93 | 7.94 | [0.5 - 2] |
Total Score | 12.05 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | 13.35 | 1.000 | 8.75 | 0 | [1 - 100] |
returnOnEquityTTM | 0.315 | 2.50 | 8.47 | 10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | 5.62 | 2.00 | 8.13 | 10.00 | [0 - 30] |
dividendYielPercentageTTM | 3.90 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | 7.05 | 2.00 | 7.65 | 10.00 | [0 - 30] |
payoutRatioTTM | 0.498 | 1.500 | 5.02 | -5.02 | [0 - 1] |
pegRatioTTM | -3.09 | 1.500 | -10.00 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0.283 | 1.000 | 5.41 | 0 | [0.1 - 0.5] |
Total Score | 5.17 |
Novartis AG
Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology, dermatology, respiratory, cardiovascular, renal, and metabolism medicine products. The Sandoz segment develops, manufactures, and markets finished dosage form medicines; active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties; and retail generics and anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.
About Live Signals
The live signals presented on this page help determine when to BUY or SELL NA. The signals have upwards of a 1-minute delay; like all market signals, there is a chance for error or mistakes.
The live trading signals are not definite, and getagraph.com hold no responsibility for any action taken upon these signals, as described in the Terms of Use. The signals are based on a wide range of technical analysis indicators